Short-term effect of intravitreal dexamethasone implant in refractory diabetic macular edema
Abstract Purpose To evaluate the short-term effects (hours-days) of intravitreal dexamethasone implant (IDI) in eyes with diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (VEGF) injections. Methods This was a prospective, single-arm, interventional clinical series....
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-03-01
|
| Series: | BMC Ophthalmology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12886-024-03341-9 |
| _version_ | 1827316113480876032 |
|---|---|
| author | Jazmín Baca Moreno David Berrones Medina María Fernanda Rosellón-Escobar José Gerardo García-Aguirre |
| author_facet | Jazmín Baca Moreno David Berrones Medina María Fernanda Rosellón-Escobar José Gerardo García-Aguirre |
| author_sort | Jazmín Baca Moreno |
| collection | DOAJ |
| description | Abstract Purpose To evaluate the short-term effects (hours-days) of intravitreal dexamethasone implant (IDI) in eyes with diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (VEGF) injections. Methods This was a prospective, single-arm, interventional clinical series. Eyes with DME and 3–9 injections of ranibizumab without a good response were included. Patients underwent a single IDI. Best-corrected visual acuity (BCVA) measurement, complete ophthalmic evaluation, and spectral-domain optical coherence tomography (SD-OCT) were performed at baseline, 2 h, 3 h, 24 h, 7 days, and 1 month. The main outcomes were change in central retinal thickness (CRT) on SD-OCT and BCVA. Results Fifteen eyes of 15 patients were included. Mean CRT decreased after treatment from 515.87 µm ± 220.00 µm at baseline to 489.60 µm ± 176.53 µm after 2 h (p = 0.126), and 450.13 µm ± 163.43 at 24 h (p = 0.006). Change in BCVA was from 0.85 ± 0.44 logMAR baseline to 0.58 ± 0.37 log MAR at 1 month (p = 0.003). Conclusions Eyes treated with IDI showed significant decrease in CRT detectable 1 day after injection. In some patients, the effect could be observed 3 h post-implantation. Trial registration Clinicaltrials.gov NCT05736081 . Registered 20 February 2023, Retrospectively registered. |
| first_indexed | 2024-04-24T23:09:14Z |
| format | Article |
| id | doaj.art-629feae6a9344075a7bd5dde31701711 |
| institution | Directory Open Access Journal |
| issn | 1471-2415 |
| language | English |
| last_indexed | 2024-04-24T23:09:14Z |
| publishDate | 2024-03-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Ophthalmology |
| spelling | doaj.art-629feae6a9344075a7bd5dde317017112024-03-17T12:19:07ZengBMCBMC Ophthalmology1471-24152024-03-012411710.1186/s12886-024-03341-9Short-term effect of intravitreal dexamethasone implant in refractory diabetic macular edemaJazmín Baca Moreno0David Berrones Medina1María Fernanda Rosellón-Escobar2José Gerardo García-Aguirre3Retina Department, Asociación para Evitar la Ceguera en México I.A.P.Retina Department, Asociación para Evitar la Ceguera en México I.A.P.Retina Department, Asociación para Evitar la Ceguera en México I.A.P.Retina Department, Asociación para Evitar la Ceguera en México I.A.P.Abstract Purpose To evaluate the short-term effects (hours-days) of intravitreal dexamethasone implant (IDI) in eyes with diabetic macular edema (DME) refractory to anti-vascular endothelial growth factor (VEGF) injections. Methods This was a prospective, single-arm, interventional clinical series. Eyes with DME and 3–9 injections of ranibizumab without a good response were included. Patients underwent a single IDI. Best-corrected visual acuity (BCVA) measurement, complete ophthalmic evaluation, and spectral-domain optical coherence tomography (SD-OCT) were performed at baseline, 2 h, 3 h, 24 h, 7 days, and 1 month. The main outcomes were change in central retinal thickness (CRT) on SD-OCT and BCVA. Results Fifteen eyes of 15 patients were included. Mean CRT decreased after treatment from 515.87 µm ± 220.00 µm at baseline to 489.60 µm ± 176.53 µm after 2 h (p = 0.126), and 450.13 µm ± 163.43 at 24 h (p = 0.006). Change in BCVA was from 0.85 ± 0.44 logMAR baseline to 0.58 ± 0.37 log MAR at 1 month (p = 0.003). Conclusions Eyes treated with IDI showed significant decrease in CRT detectable 1 day after injection. In some patients, the effect could be observed 3 h post-implantation. Trial registration Clinicaltrials.gov NCT05736081 . Registered 20 February 2023, Retrospectively registered.https://doi.org/10.1186/s12886-024-03341-9Diabetic macular edemaOzurdexIntravitreal dexamethasone |
| spellingShingle | Jazmín Baca Moreno David Berrones Medina María Fernanda Rosellón-Escobar José Gerardo García-Aguirre Short-term effect of intravitreal dexamethasone implant in refractory diabetic macular edema BMC Ophthalmology Diabetic macular edema Ozurdex Intravitreal dexamethasone |
| title | Short-term effect of intravitreal dexamethasone implant in refractory diabetic macular edema |
| title_full | Short-term effect of intravitreal dexamethasone implant in refractory diabetic macular edema |
| title_fullStr | Short-term effect of intravitreal dexamethasone implant in refractory diabetic macular edema |
| title_full_unstemmed | Short-term effect of intravitreal dexamethasone implant in refractory diabetic macular edema |
| title_short | Short-term effect of intravitreal dexamethasone implant in refractory diabetic macular edema |
| title_sort | short term effect of intravitreal dexamethasone implant in refractory diabetic macular edema |
| topic | Diabetic macular edema Ozurdex Intravitreal dexamethasone |
| url | https://doi.org/10.1186/s12886-024-03341-9 |
| work_keys_str_mv | AT jazminbacamoreno shorttermeffectofintravitrealdexamethasoneimplantinrefractorydiabeticmacularedema AT davidberronesmedina shorttermeffectofintravitrealdexamethasoneimplantinrefractorydiabeticmacularedema AT mariafernandarosellonescobar shorttermeffectofintravitrealdexamethasoneimplantinrefractorydiabeticmacularedema AT josegerardogarciaaguirre shorttermeffectofintravitrealdexamethasoneimplantinrefractorydiabeticmacularedema |